Episode 16 - Neurofibromatosis Type 1-related Plexiform Neurofibromas: Key Advances from the 2025 Annual Oncology Conference (Chicago)

The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.Launch Date: June 5, 2025Release Date: June 5, 2025Expiration Date: May 31, 2026FACULTYAmy Armstrong, MDAssistant Professor of PediatricsDivision of Hematology/OncologyNeurofibromatosis (NF) CenterWashington University School of MedicineSt. Louis, MissouriThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.